-
701
-
702
-
703
Microarray analysis from GEO database showed TNFAIP9 was enhanced in CKD patients and mice.
منشور في 2025الموضوعات: -
704
Overexpression of TNFAIP9 alleviated the renal fibrosis caused by 5/6 Nx in C57 mice.
منشور في 2025الموضوعات: -
705
Overexpression of TNFAIP9 inhibits the weight loss caused by 5/6 Nx in C57 mice.
منشور في 2025الموضوعات: -
706
Overexpression of TNFAIP9 inhibited the TNF-α-induced inflammation in HK-2 cells.
منشور في 2025الموضوعات: -
707
-
708
Overexpression of TNFAIP9 remitted the renal inflammation caused by 5/6 Nx in C57 mice.
منشور في 2025الموضوعات: -
709
-
710
Overexpression of TNFAIP9 inhibited the TGF-β-induced fibrosis in HK-2 cells.
منشور في 2025الموضوعات: -
711
Overexpression of TNFAIP9 counteracted the renal damage caused by 5/6 Nx in C57 mice.
منشور في 2025الموضوعات: -
712
Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
713
Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
714
Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
715
Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
716
Table 4_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
717
Table 6_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
718
Table 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
719
Table 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"
-
720
Image 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg
منشور في 2025"…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …"